We’re excited to share an important milestone at PurpleLab: we’ve officially submitted our first-ever response to a federal Request for Comment (RFC), and it’s now live on regulations.gov. Ann Phillips, our Senior Director of Regulatory and Standards, pulled together an impressive response to the FDA’s RFC focused on the use of HL7 FHIR (Fast Healthcare…

Healthcare is evolving. We used to focus purely on addressing specific symptoms and treating specific diseases. Our understanding of medicine and medical care was shaped by biology and what goes on inside the body.  But we now know that our health outcomes are also significantly shaped by external factors – everything from our ZIP code…

Rate Explorer is the only self-service platform that provides real-time exploration of contracted rates across all payers, health plans, care delivery organizations, and services. Accurately conduct analyses to surface actionable pricing insights to inform healthcare pricing and strategy to increase overall financial viability. Watch the video to see how.

This research, led by Grace K. Kane, Douglas Londono, and Nathan J. Markward, explores how the timing of biomarker testing affects survival outcomes in patients with non-small cell lung cancer (NSCLC). Using real-world claims data, it identifies disparities in testing and treatment patterns and their impact on mortality rates. Biomarker testing is essential to advancing…

Price transparency mandates have introduced an unprecedented volume of data — but turning that data into actionable strategy remains a challenge. Health systems and payers alike are still navigating how to translate pricing insights into stronger contract terms, smarter network expansion and more aligned pricing strategies.

Using non-small cell lung cancer (NSCLC) as an example, PurpleLab and Genentech will explore how to leverage RWD to eliminate blind spots in the patient journey.

At ISPOR 2025 in Montreal, PurpleLab presented a research poster titled “Trends in Attainment of the Kidney Health Evaluation for Patients with Diabetes Measure among Insured Individuals in the US, 2021-2024”. The study, conducted by Stephan Dunning, MBA, MS, Douglas Londono, PhD, Yeison Ortiz, BS, Anna Wang, PhD, Nathan Markward, PhD, MPH, and Steven Emrick, BS,…

At ISPOR 2025 in Montreal, PurpleLab presented a research poster titled “Intersectional Multilevel Analysis of Individual Heterogeneity and Discriminatory Accuracy (MAIHDA) for Social Determinants of Health and Pregnancy Outcomes.” The study, conducted by Anna Wang, PhD, Francis Concannon, BS, Daria Eremina, PhD, and Douglas Londono, PhD, applied MAIHDA to analyze how overlapping social factors influence…

Real-World Data: The Cornerstone of Life Science Consulting Life sciences are at an inflection point. As pressure mounts to develop therapies faster, prove real-world value to payers, and personalize interventions, traditional data sources are hitting their limits. Real-world data (RWD), particularly claims data, has emerged as a critical lever across the product lifecycle. For consultancies,…